29 05, 2020

microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring

2020-05-29T10:03:50+02:00May 29th, 2020|biomarker, biomarkers, microRNA, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR|0 Comments

We want to draw your attention to the latest review of TAmiRNA and the King's College London, in Cardiovascular Diabetology. "microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring." Krammer TL, Mayr M & Hackl M. Int. J. Mol. Sci. 2020, 21(10), 3477; doi.org/10.3390/ijms21103477 In this review, we explain the secretion of miRNAs upon platelet activation and discuss the potential use of platelet-related miRNAs as biomarkers for CVD and antiplatelet therapy monitoring, but also highlight remaining gaps in our knowledge and uncertainties regarding clinical utility. click here to read the story

13 01, 2020

New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

2020-01-13T11:11:00+01:00January 13th, 2020|biomarker, biomarkers, clopidogrel, diabetes, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR, type 2 diabetes mellitus|0 Comments

We want to draw your attention to the latest publication of the King's College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response in type-2 diabetics with cardiovascular disease. "Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels." Parker WAE, Schulte C, Bawari T, et al. Cardiovasc Diabetol. 2020 Jan 7;19(1):3. doi: 10.1186/s12933-019-0981-3. click here to read the story